ERBB2 and breast cancer: Another study, involving 6712 breast cancer patients showed a decrease in the number of CTCs only in human epidermal growth factor receptor 2 (HER2+) or HER2- patients but not in the triple-negative ones and nor in patients who underwent surgery.